Background: We investigated tumor regression grading (TRG) as a prognostic marker and individual-level surrogate for diseasefree survival (DFS) in patients with rectal carcinoma treated within the Chirurgische Arbeitsgemeinschaft fur Onkologie/ Arbeitsgemeinschaft Radiologische Onkologie/Arbeitsgemeinschaft Internistische Onkologie (CAO/ARO/AIO)-04 randomized trial. Methods: TRG was recorded prospectively using the Dworak classification in 1179 patients after preoperative fluorouracilbased chemoradiotherapy (CRT) with or without oxaliplatin. Multivariable analysis was performed using Cox regression models adjusted for treatment arm, resection status, and pathologic stage. Individual-level surrogacy of TRG for DFS was examined using the four Prentice criteria (PC1-4). All statistical tests were two-sided. Results: With a median follow-up of 50 months, the addition of oxaliplatin to fluorouracil-based CRT led to statistically significantly improved three-year DFS (75.9%, 95% CI ¼ 72.3 to 79.5, vs 71.3%, 95% CI ¼ 67.6 to 74.9, P ¼ .04, PC 1) and a shift toward more advanced TRG groups (P < .001, PC 2) compared with CRT with fluorouracil alone. The three-year DFS was 64.6% (95% CI ¼ 57.3 to 71.9), 77.6% (95% CI ¼ 74.5 to 80.7), and 92.3% (95% CI ¼ 88.4 to 96.2) for TRG 0 þ 1 (poor regression), TRG 2 þ 3 (intermediate regression), and TRG 4 (complete regression), respectively (P < .001, PC 3). TRG constituted an independent prognostic factor for DFS (TRG 2 þ 3 vs TRG 0 þ 1, HR ¼ 0.68, 95% CI ¼ 0.51 to 0.90, P ¼ .007). Due to multicollinearity, TRG 4 and pathologic stage could not be tested within the same model. The treatment effect on DFS was captured by TRG, satisfying individual-level PC4. Conclusions: Higher TRG after preoperative CRT predicted a favorable long-term outcome. At the individual patient level, TRG was a surrogate marker for DFS. Further phase III trials are needed to validate TRG as a surrogate at trial level.
The management of rectal carcinoma has improved substantially during the past 20 years. Preoperative 5-fluorouracil-(5-FU)-based chemoradiotherapy (CRT) followed by total mesorectal excision (TME) six weeks thereafter, or short-course radiotherapy (RT) followed by immediate TME, has substantially reduced local recurrences (1, 2) . However, long-term follow-up for these trials failed to demonstrate an improvement in either disease-free (DFS) or overall survival (OS) (3, 4) . More recent developments in multimodal rectal cancer treatment have incorporated combination chemotherapy beyond 5-FU, and/or molecularly targeted agents, before, during, or following preoperative (or definitive) CRT/RT (5) .
With the use of preoperative treatment rather than upfront surgery, it has become evident that the response of rectal carcinoma to CRT/RT varies considerably. Traditionally, downsizing and downstaging-as documented by a decrease in size of the primary tumor, or the pathologic vs preoperative clinical T and N category-have been used to measure tumor response to CRT/RT (6, 7) . We have previously shown that tumor regression grading (TRG), a semiquantitative assessment of residual tumor cells vs fibroinflammatory tissue in the rectal wall, was able to stratify tumor response to CRT and predict prognosis on an individual-patient level: A five-tier TRG system (later regrouped to three-tier), used as a secondary end point in the Chirurgische Arbeitsgemeinschaft fur Onkologie/Arbeitsgemeinschaft Radiologische Onkologie/ Arbeitsgemeinschaft Internistische Onkologie (CAO/ARO/AIO)-94 trial, identified distinct prognostic groups independent of established prognostic factors such as the Union for International Cancer Control-TNM classification system (8, 9) .
Accumulative evidence from other studies confirmed the potential role for TRG as a prognostic parameter, albeit definitions and reported systems differ and vary from three to five groups (10, 11) . Moreover, despite the use of pathologic complete response (pCR: ypT0N0 that greatly overlaps with complete tumor regression) to predict outcome (12) , the majority of studies investigating the prognostic value of TRG included heterogeneous patient cohorts treated with different regimens, were conducted retrospectively, and are thus prone to biases and difficult to interpret. In the present work, we describe the prognostic value of TRG in the next-generation CAO/ARO/AIO-04 randomized phase III trial (13, 14) . This large randomized phase III trial showed a DFS benefit following the addition of oxaliplatin to 5-FU-based combined modality treatment. TRG was recorded prospectively in both arms of the study according to Dworak et al. (15) . The aims of this present study were 1) to assess the prognostic value of the TRG system both in univariate and multivariable analyses, taking well-established clinicopathologic factors into account, and 2) to determine whether TRG could serve as an individuallevel efficacy-response surrogate for the primary end point, DFS, using the Prentice criteria (16) .
Methods

Study Design and Participants
The CAO/ARO/AIO-04 trial (ClinicalTrials.gov, No. NCT00349076) was a multicenter, open-label, two arm randomized phase III study approved by the ethics committee of the University of Erlangen. Each recruited patient provided written informed consent. The design, eligibility and exclusion criteria, treatment plan, and outcome have been described elsewhere (13, 14) . A brief description is provided in the Supplementary Methods (available online), and the treatment plan is shown in Supplementary Figure 1 (available online). The full trial protocol (English and German versions) is provided as Supplementary Material (available online).
Pathologic Examination and Definition of TRG
The protocol included the TNM classification based on the American Joint Committee on Cancer and International Union Against Cancer (sixth edition), analysis of lymph nodes (total and involved), and the status of proximal, distal, and circumferential resection margins (R0 for negative margins, R1 for microscopically involved margins, and R2 for macroscopically visible gross residual tumor).
Processing and analysis of the resected specimen has been described before (8, 9) and is described in the Supplementary Methods (available online). The residual tumor mass after preoperative treatment was assessed semiquantitatively in 1179 patient specimens considering the amount of viable tumor and fibrotic tissue according to the five-point TRG system by Dworak et al. (15) . The five-tier classification included TRG 4 
Follow-up
The follow-up procedure is described in detail in the Supplementary Methods (available online).
Statistical Analysis
The associations between TRG and treatment arms (as received), pretreatment clinicopathologic characteristics, and postsurgical pathologic factors were assessed by a conditional linear-by-linear permutation test, stratified with respect to treatment, taking ordinal measurement scales into account. DFS was defined as the time between random assignment and either macroscopically visible gross tumor after surgery (R2 resection), locoregional recurrence after R0/1 resection of the primary tumor, distant metastases or progression, or death from any cause, whichever occurred first. The cumulative incidence of locoregional and distant recurrence was defined as the time between random assignment and occurrence of any locoregional recurrence (after R0/1 resection of the primary tumor) and distant recurrence, respectively, irrespective of whether this was a first event or not. Overall survival (OS) was defined as time from random assignment to death from any cause. We performed univariate analyses using the log-rank test, stratified by treatment arm. The cumulative incidence of locoregional and distant recurrences was assessed with death as competing risk in univariate analysis. For postsurgical parameters, all end points were calculated from date of surgery in univariate and multivariable analyses to prevent length bias (17) .
Multivariable analyses were performed using the Cox model for DFS and OS and the Fine-Gray model for cumulative incidence of locoregional and distant recurrences. Patients with missing values in one or more of the variables were excluded. The prognostic value of TRG for the respective end points was assessed by adding grouped TRG 0 þ 1 and TRG 2 þ 3 to the initial Cox or Fine-Gray models while retaining the estimated hazard ratios of the initial models. The additional prognostic value of TRG 4 could not be assessed due to the large patient overlap with ypT0N0 that would inevitably lead to multicollinearity and thus statistical bias. The Wald test was used to examine whether adding TRG 0þ1 vs 2þ3 statistically significantly improved the prognostic accuracy of the established parameters.
The four Prentice criteria (PC 1-4) were applied to assess TRG surrogacy for DFS at the individual-patient level (16) . First, treatment must have statistically significant impact on DFS (PC 1). Second, treatment must have statistically significant impact on TRG (PC 2). Third, TRG must have statistically significant effect on DFS (PC 3), and, fourth, the full effect of treatment on DFS should be captured by TRG (PC 4). PC 1 to 3 were ARTICLE assessed using log-rank and linear-by-linear association tests; the treatment effect on TRG was assessed by the odds ratio in a proportional odds logistic regression. Nonproportionality of the odds scale was ruled out by application of a nonproportional odds logistic regression model. PC 4 was evaluated by a Cox model for DFS based on TRG and treatment, stratified by local resection status and pathologic stage according to Buyse et al. (18) . To prevent length bias, DFS was again calculated from date of surgery (17) . All statistical tests were two-sided, and a P value less than .05 was considered statistically significant for all analyses.
A detailed description of all statistical analyses, including additional sensitivity analyses, with patient data and computer codes, is available on the official homepage of the CAO/ARO/ AIO-04 clinical trial (http://www.caoaroaio04.org). Further details on the statistical analysis are provided in the Supplementary Methods (available online).
Results
Patient Characteristics and Association of TRG With Clinicopathologic Factors
Between July 2006 and February 2010, 1265 patients were recruited, of whom 29 patients were excluded because they did Table 3 . Association of tumor regression grading with pathologic factors after 5-FU-based CRT þ/À oxaliplatin and surgery Table 1 . For both the five-tier and grouped three-tier TRG, 5-FU/OX-CRT led to a statistically significant shift toward higher TRG groups compared with the 5-FU-CRT arm (P ¼ .002 and P ¼ .001, respectively) ( Table 1) . For further analysis, we used the three-tier TRG grouping (complete regression, TRG 4; intermediate regression, TRG 2 þ 3; and poor regression, TRG 0 þ 1) as established in our previous reports (8, 9) . For DFS, TRG 4, TRG 2 and 3, and TRG 0 and 1 clustered together, further justifying the three-trier TRG grouping (8, 9) . We failed to observe an association of TRG with any of the pretreatment clinicopathologic parameters (Table 2 ). In contrast, TRG was statistically significantly associated with several pathologic factors after preoperative CRT and surgery, including completeness of surgical resection, ypT, ypN, pathologic stage, and circumferential resection margin (CRM) ( Table 3) . Similarly, higher TRG statistically significantly associated with a longer interval (median or quartiles) between completion of preoperative CRT and surgery (Table 3 ).
The Prognostic Value of TRG for Clinical Outcome
The median follow-up was 50 months (interquartile range ¼ 38-61 months). The three-year DFS and cumulative incidence of local recurrences after R0/1 resection for the entire cohort were 73.6% (95% CI ¼ 71.0% to 76.1%) and 3.2% (95% CI ¼ 2.1% to 4.2%), respectively. The three-year cumulative incidence of distant recurrences and OS were 20.6% (95% CI ¼ 18.2% to 22.9%) and 88.4% (95% CI ¼ 86.5% to 90.3%), respectively (Table 4) .
We assessed the prognostic impact of TRG on DFS, the cumulative incidence of local recurrence after R0/R1 surgery, cumulative incidence of distant metastasis, and OS in univariate analysis (Table 4 and Figure 1 ). The three-year DFS was 64.6% (95% CI ¼ 57.3% to 71.9%), 77.6% (95% CI ¼ 74.5% to 80.7%), and 92.3% (95% CI ¼ 88.4% to 96.2%) for TRG 0 þ 1, TRG 2 þ 3, and TRG 4, respectively (P < .001). TRG was statistically significantly associated with the three-year cumulative incidence of local recurrence (6.9%, 95% CI ¼ 3.2% to 10.7%, 3.3%, 95% CI ¼ 1.9% to 4.6%, and 0% for TRG 0 þ 1, TRG 2 þ 3, and TRG 4, respectively, P < .001) and distant metastasis (25.4%, 95% CI ¼ 18.9% to 31.9%, 18.3%, 95% CI ¼ 15.4% to 21.2%, and 4.1%, 95% CI ¼ 1.2% to 7.0%, for TRG 0 þ 1, TRG 2 þ 3, and TRG 4, respectively, P < .001). Also, patients with TRG 4 had a statistically significantly better threeyear OS compared with TRG 2 þ 3 and TRG 0 þ 1 (96.2%, 95% CI ¼ 93.4% to 99.0%, 89.2%, 95% CI ¼ 86.9% to 91.5%, and 76.8%, 95% CI ¼ 70.6% to 83.0%, respectively, P < .001) (Table 4) .
Furthermore, we investigated the prognostic significance of treatment arms and various clinicopathologic factors in univariate analysis, and the results are found in Table 4 . The addition of oxaliplatin to 5-FU-based CRT was associated with improved DFS (75.9%, 95% CI ¼ 72.3% to 79.5%, vs 71.3%, 95% CI ¼ 67.6% to 74.9%, P ¼ .04) and local control (P ¼ .02). Pathologic stage, ypT, and ypN constituted prognostic factors for all four clinical end points (P < .001 in each case). Circumferential resection margin showed statistical significance for DFS (P < .001), cumulative incidence of distant metastasis (P < .001), local recurrence (P < .001), and OS (P ¼ .04). Completeness of resection showed statistical prognostic significance for better DFS (P ¼ .01) and OS (P < .001). Older age showed statistical prognostic significance for worse OS (P ¼ .001).
We subsequently performed a multivariable analysis for all four end points, and the results are presented in Table 5 . Due to multicollinearity, ypT/ypN, TRG 4, and pathologic stage could not be tested within the same model. CRM was excluded due to the large number of missing/unknown cases to avoid undermining the statistical power of the analysis. TRG 2 þ 3 vs TRG 0 þ 1 after preoperative CRT constituted an independent prognostic factor for DFS (HR ¼ 0.68, 95% CI ¼ 0.51 to 0.90, P ¼ .007), the cumulative incidence of local recurrence (HR ¼ 0.50, 95% CI ¼ 0.27 to 0.93, P ¼ .03), and OS (HR ¼ 0.58, 95% CI ¼ 0.42 to 0.80, P < .001). Advanced pathologic stage was prognostic for worse outcome for all four clinical end points in multivariable analysis. Complete resection (R0) predicted for better DFS (P ¼ .006), local control (P ¼ .04), and OS (P < .001). The experimental treatment arm was associated with better local control (P ¼ .009).
TRG as a Surrogate Marker for DFS
For the evaluation of TRG as a surrogate end point for DFS at an individual-patient level, the four Prentice criteria (16-18) were tested: PC 1 (statistically significant treatment effect on DFS, P ¼ .04) ( Table 4) and PC 3 (statistically significant association ARTICLE between grouped three-tier TRG and DFS, P < .001) ( Table 4) were met. The common treatment effect of TRG 2þ3 vs TRG 0þ1 and TRG 4 vs TRG 2þ3 assessed by the odds ratio in a proportional odds logistic regression was 1.523 (P < .001), indicating that the TRG distribution was shifted toward higher grades in the experimental arm, satisfying PC 2. PC 4 requires that the treatment arm is independent of DFS once the surrogate is accounted for. PC 4 was assessed using a stratified multivariable Cox model for DFS, taking treatment arm and TRG into account. The formerly statistically significant treatment effect on DFS vanished from this model (HR ¼ 0.84, 95% CI ¼ 0.66 to 1.08, P ¼ .17), while TRG 2 þ 3 vs TRG 0 þ 1 still retained its impact on DFS (HR ¼ 0.68, 95% CI ¼ 0.52 to 0.91, P ¼ .009) (data not shown). This indicates that the treatment effect on DFS was captured by TRG, satisfying individual-level PC 4. Due to a lack of power, however, we could not formally demonstrate that the hazard ratio was equal to 1 after adjustment for TRG because the 95% confidence interval for the hazard ratio was 0.66 to 1.08. Additional sensitivity analyses to further support satisfaction of PC 4 and TRG surrogacy were conducted as described in the Supplementary Methods (available online). For that purpose, we performed two additional Cox models for DFS after surgery. In the first model, we stratified with respect to TRG (ignoring the other prognostic variables) and re-estimated the treatment effect. We added the local resection status and pathological stage to this model in a second step. The 95% confidence intervals for the corresponding treatment effects were 0.68 to 1.10 (HR ¼ 0.87) and 0.66 to 1.07 (HR ¼ 0.84), respectively No. at risk Figure 1 . Prognostic significance of TRG after preoperative chemoradiotherapy and TME surgery in rectal carcinoma. A) Prognostic significance of TRG for disease-free survival. B) Prognostic significance of TRG for cumulative incidence of local recurrence. C) Prognostic significance of TRG for cumulative incidence of distant metastases. D) Prognostic significance for overall survival in patients with TRG 0 þ 1 (poor regression), TRG 2 þ 3 (intermediate regression) and TRG 4 (complete regression). Please note the different numbers at risk per definition of the different clinical end points below each graph. The log-rank test, stratified by treatment arm was used to assess statistical significance. The cumulative incidence of locoregional and distant recurrences was assessed with death as competing risk in univariate analysis. All endpoints were calculated from date of surgery. The statistical test was two-sided. Table 5 . Multivariable analysis of different variables on disease-free survival, cumulative incidence of distant metastases and local recurrences, and overall survival*
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No. .38 0.95 (0.71 to 1.27) . was assessed by adding grouped TRG 0 þ 1 and TRG 2 þ 3 to the initial Cox or Fine-Gray models while retaining the estimated hazard ratios of the initial models. The statistical test was two-sided. ‡Patients with R2 resection were also included in the multivariable analysis for cumulative incidence of distant metastases and overall survival. §The additional prognostic value of TRG 4 could not be assessed because of the large patient overlap with ypT0N0 that would inevitably lead to multicollinearity.
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(data not shown). Thus, the additional sensitivity analyses support the conclusion that adjustment for TRG removed the treatment effect, satisfying PC 4.
Discussion
Preoperative therapy has become standard of care for a variety of gastrointestinal tumors. Tumor response to homogeneous preoperative treatment shows a great variety that ranges from histopathologically confirmed complete tumor regression to essentially complete lack of response. In rectal cancer, tumor response depends on several factors, such as the dose and the schedule of the preoperative treatment (either chemotherapy, RT, or their combination), the time between treatment and surgery, and, probably most important, tumor biology (11, 12, (19) (20) (21) .
Here, we examined the prognostic role of TRG in a large patient cohort treated as part of the CAO/ARO/AIO-04 randomized phase III trial. In line with our previous studies (8, 9) , the grouped three-tier TRG classification was a prognostic factor for DFS, independent of well-established prognostic parameters such as local resection status and pathologic stage. Other studies, based on large retrospective single-institution colorectal databases, have confirmed the prognostic value of TRG, albeit systems differed with respect to definitions and varied from three to five groups (10, 11) . The American Joint Committee on Cancer/College of American Pathologists' four-tier TRG system was recently confirmed to carry independent prognostic value after adjusting for statistically significant covariates, including pathologic stage (11) . Thus, cumulative findings from our multicenter prospective trials and large single-center databases highlight the importance of reporting TRG as part of the daily routine pathologic work-up.
Why does TRG-a simple assessment of the amount of residual tumor vs fibrosis in the rectal wall-carry such important prognostic information? Evidently, less extensive or even complete lack of tumor regression reflects an aggressive malignant phenotype that is at the same time less responsive to CRT and exhibits higher propensity to metastasize. An important implication of this concept would be that the biologic mechanisms that mediate resistance to CRT and distant cancer cell spread are closely linked or even overlap with each other. Accordingly, pathophysiological mechanisms, such as hypoxia and angiogenesis (22) , oncogenic activation (23), epithelial-mesenchymal transition (24) , and resistance to apoptosis, (25) result in local tumor resistance to CRT and increase the propensity to develop metastases.
In line with previous reports (26, 27) , longer waiting periods between CRT completion and surgery led to increased tumor regression in our trial. The mechanisms behind this clinical observation remain unclear and cannot be possibly explained by the classical "5Rs" of radiobiology (repopulation, redistribution, repair, reoxygenation, and radiosensitivity) that determine tumor response to radiotherapy (28) . Radiation-induced cancer cell death can trigger the innate immune system (29), whereas enhanced infiltration by cytotoxic T cells has been reported post-CRT in rectal cancer (30) . Thus, the association between more advanced TRG and longer interval between CRT completion and surgery could reflect an activated immune response that continuously exerts its antitumorigenic effect during the waiting period before TME, and it could also explain, at least partly, the prognostic statistical significance of advanced TRG for lower incidence of metastases.
The second aim of this analysis was to determine whether TRG may be used as an early individual-level surrogate for the primary end point of DFS based on the four Prentice criteria of individual patient-level surrogacy (16) . Validating short-term surrogates in randomized trials becomes increasingly recognized. Long-term end points, such as DFS and OS, are expensive, time consuming, require a large sample size, and are associated with the risk of the investigated treatment losing novelty by the time of trial completion (18) . Here we show for the first time that TRG was an independent predictor of favorable DFS and met the Prentice criteria 1 to 3 for DFS surrogacy within a randomized phase III trial. Fulfilling the fourth Prentice criterion poses a major challenge as it requires a complete lack of treatment effect on DFS after adjustment for TRG. Although treatment effect on DFS lost its statistical significance in the Cox model (HR ¼ 0.84, P ¼ .17), the range of the confidence interval was wide (95% CI ¼ 0.66 to 1.08), suggesting that the CAO/ARO/ AIO-04 trial was not adequately powered for such a strict analysis. Nevertheless, we found that the treatment effect on DFS was captured by TRG because TRG2 þ 3 vs TRG 0 þ 1 retained its statistically significant impact on DFS, satisfying individuallevel PC 4.
Assessment of TRG effects based on meta-analysis of large randomized trials is a prerequisite for the validation of its surrogacy at both the individual and trial levels (18) , extending beyond the Prentice criteria. To our knowledge, this is the first large phase III trial in rectal cancer to examine the surrogacy of TRG for DFS, and it hence paves the path for future similar studies.
Our study has limitations. First, there was no central pathology review. Second, analysis of inter-and intraobserver variability of TRG scoring was not conducted. Third, despite the well-defined Dworak classification for TRG evaluation used in the present work, there is still a lack of consensus for a universally approved regression classification.
In conclusion, higher TRG after preoperative CRT was associated with statistically significantly better clinical outcome and provided additional information after adjusting for treatment arm, local resection status, and pathologic stage. In the era of personalized medicine, TRG as an early available end point may help to validate predictive molecular biomarkers, to identify the most promising preoperative treatment strategy within early clinical trials for larger-scale testing, and facilitate responseguided therapeutic strategies. Further appropriately powered phase III trials should be conducted to foster implementation of TRG as a validated surrogate end point for DFS at both the individual-patient level and trial level.
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